

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/535,545	FERRANDIS, ERIC	
	<b>Examiner</b> LYNN BRISTOL	<b>Art Unit</b> 1643	
<b>All Participants:</b>		<b>Status of Application:</b> <u>allowed</u>	
(1) LYNN BRISTOL		(3) _____	
(2) Christopher Nichols.		(4) _____	
<b>Date of Interview:</b> <u>8 September 2009</u>		<b>Time:</b> <u>10:40 AM</u>	
<b>Type of Interview:</b>			
<input checked="" type="checkbox"/> Telephonic <input type="checkbox"/> Video Conference <input type="checkbox"/> Personal (Copy given to: <input type="checkbox"/> Applicant <input type="checkbox"/> Applicant's representative)			
Exhibit Shown or Demonstrated: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
If Yes, provide a brief description: .			
<b>Part I.</b>			
Rejection(s) discussed: <i>not applicable</i>			
Claims discussed: <i>10 and 23-44</i>			
Prior art documents discussed: <i>not applicable</i>			
<b>Part II.</b>			
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: <i>See Continuation Sheet</i>			
<b>Part III.</b>			
<input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. <input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.			
<i>/Lynn Bristol/ Art Unit 1643 Temporary Full Signatory Authority</i>			
(Applicant/Applicant's Representative Signature – if appropriate)			

Continuation of Substance of Interview including description of the general nature of what was discussed: deleting "and having" clause from element (a) of Claim 10 which otherwise describes the polynucleotide as having the biological properties; deleting the phrase in element (b) of Claim 10 and in Claims 25, 31 and 39 for " has at least one immunological and/or biological activity characteristic of a protein binding human GHRH" and replacing the phrase with "where said polypeptide is heterocarpine" in order to clarify the subject matter for the encoded protein and which properties are otherwise inherent to heterocarpine.